Phase 2/3 Trial Will Evaluate Bardoxolone Methyl as Treatment for Alport-related CKD
News
Reata Pharmaceuticals has begun screening patients for the new Phase 2/3 trial evaluating bardoxolone methyl as a treatment for patients of Alport syndrome-associated chronic kidney disease (CKD). The aim of ... Read more